Navigation Links
Halozyme Therapeutics Announces Public Offering of Common Stock
Date:9/8/2010

y from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.Halozyme Contact  Robert H. UhlSenior Director, Investor Relations(858) 704-8264ruhl@halozyme.com
'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ... decade has seen the atopic dermatitis market ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger ... and painless for patients to self-inject prescription drugs in ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and ... market is expected to grow to $220B by 2018, ... a new type of injector that does not exist ...
(Date:1/14/2014)... -- Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of ... Home Medical Equipment, Inc. ("Progressive") of Clarion, PA ... acquisition were not disclosed. Progressive is a ... range of sleep, mobility, and respiratory products to customers in ... Pittsburgh markets. Progressive was founded in 2005 by ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... N.J., Nov. 4, 2010 Savient Pharmaceuticals, Inc. (Nasdaq: ... to commence shipments of KRYSTEXXA™ to specialty distributors on ... enzyme indicated for the treatment of chronic gout in ... to be commercially available for prescription as of December ...
... Nov. 4, 2010 Stanley M. Chesley of the Cincinnati, ... L.P.A. earlier today filed a major class action lawsuit against ... DePuy and Johnson and Johnson recently recalled over ... an unacceptable failure rate causing patients to undergo hip replacement ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 2Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 3Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 4Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 5Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 6Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 7
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... New Report Details the Structure and Funding Of U.S. ... With attention to global health rising on the ... Foundation today launched a set of new resources providing ... the global health arena with timely information, including daily ...
... Value Is Through A Sale to A Strategic Acquirer.RALEIGH, ... stockholder of BioScrip, Inc. (Nasdaq: BIOS ), ... the Board of Directors of BioScrip in which Anchor ... through simultaneous i) cost rationalizations and ii) exploration of ...
... N.C., April 27 Susan Brady of ... professionals in the nation to become certified by ... nonprofit organization that provides advocacy and education for ... demonstrated in-depth knowledge and expertise on best practices ...
... Monitoring Companies Demonstrates FORA Technology at Telemedicine Conference in ... Fora Care and Fora Care Suisse AG (Fora Care,s ... innovative telemedicine program at the American Telemedicine Association (ATA) ... Casino in Las Vegas, Nev. The veteran telemedicine ...
... Daily exposure to toxins in the products we ... insecticides, are creating a toxic load on our bodies ... In light of increased awareness of our environmental exposures, ... ) announced today the release of three new testing ...
... to 10-minute soaks, twice a week, prevent painful flare-ups, ... Diluted bleach baths offer a safe, simple and inexpensive ... researchers. , The skin disease, which affects 17 percent ... their ability to concentrate in school. , Eczema-related ...
Cached Medicine News:Health News:Kaiser Family Foundation Launches Daily Global Health Policy Report and Policy Tracking Tool As Part of New Web Gateway Focusing on U.S. Global Health Policy 2Health News:Kaiser Family Foundation Launches Daily Global Health Policy Report and Policy Tracking Tool As Part of New Web Gateway Focusing on U.S. Global Health Policy 3Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 2Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 3Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 4Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 5Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 6Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 7Health News:MedThink Communications Account Director Among First to Receive CMPP Certification in Medical Publications Planning and Development 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:Diluted Bleach Baths Ease Kids' Eczema 2
... Medtronic has been a key participant ... for more than a decade. Previous Medtronic ... for concentrated platelets, as well as to ... for producing platelet-rich plasma (PRP) for a ...
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... Biliary Self-Expanding Stent System combines low-profile, high radial ... .018" guide wire compatible stent system provides 6F ... diameters (5.0 - 10.0 mm). Now, with longer ... in five stent lengths (28, 38, 56, 80 ...
... Supreme and Response catheters comprise ... catheters available for electrophysiology procedures. Their ... provide for superior torque response with ... multiple curves and French sizes, Supreme ...
Medicine Products: